Inositol for PCOS is one of the most frequently recommended supplements, and for good reason – it has a significant evidence base, a good safety profile, and addresses one of the central drivers of PCOS symptoms: insulin resistance. But the inositol market can be genuinely confusing. Myo-inositol. D-chiro-inositol. 40:1 ratios. High-dose DCI. What does the research actually support?
Having followed this research closely for decades as a clinician working with PCOS patients, I want to give you a clear, current picture of what the evidence says – including some nuances that product marketing tends to ignore and what I’ve seen ACTUALLY work.
What Is Inositol and What Does Inositol for PCOS Do?
Inositol is a naturally occurring compound in the B vitamin family, found in cell membranes throughout the body. It acts as a second messenger for insulin signalling – meaning it is part of the cascade of events that occurs when insulin binds to a cell receptor and instructs the cell to take up glucose.
In PCOS, a disruption in inositol metabolism appears to contribute to the cellular insulin resistance that drives elevated insulin, elevated androgens, and disrupted ovulation. There are nine possible forms of inositol, but only two have been meaningfully studied in PCOS: myo-inositol (MYO) and D-chiro-inositol (DCI).
Myo-Inositol for PCOS: What It Does
Myo-inositol is the most abundant form of inositol in the human body and in dietary sources. In the context of PCOS, it:
- Promotes translocation of the GLUT-4 glucose transporter to the cell membrane, improving cellular glucose uptake
- Supports FSH signalling in the ovaries, which is important for follicular development and ovulation
- Has shown benefits for insulin sensitivity, androgen levels, and menstrual regularity in RCTs
- Has fewer gastrointestinal side effects when compared to metformin
The evidence base for myo-inositol alone is positive and reasonably well-established. The 2023 International Evidence-Based PCOS Guidelines systematic review, published in the Journal of Clinical Endocrinology and Metabolism in 2024, found evidence of the benefit of myo-inositol for metabolic outcomes, though it noted that the overall evidence base remains limited and inconclusive across all outcomes.
D-Chiro-Inositol: What It Does – and the Problem With High Doses
D-chiro-inositol is produced in the body from myo-inositol via an enzyme called epimerase. DCI stimulates glycogen synthesis and supports glucose metabolism through a different pathway than MYO. Early research showed promising effects on ovulation and androgen levels in PCOS, generating significant excitement.
However, subsequent research has complicated the picture considerably. High-dose DCI supplementation alone appears to be not just ineffective but potentially harmful for ovarian function:
- High doses of DCI have been shown to impair oocyte quality
- High-dose DCI can paradoxically reduce ovarian sensitivity to FSH
- In animal studies, high doses induced PCOS-like changes in the ovaries
The 2024 narrative review published in Gynecological Endocrinology concluded that there is insufficient or controversial evidence to recommend DCI alone, while MYO alone shows positive results. This is an important distinction that many supplement companies marketing standalone DCI products fail to emphasize.
The 40:1 Ratio: What the Research Supports
The current evidence points to a combination of MYO and DCI at a specific ratio as the most effective approach. The physiological ratio of MYO to DCI in the human body is approximately 40:1, and this ratio has become the most studied formulation in clinical trials.
A clinical trial comparing seven different MYO/DCI ratios in PCOS patients found that the 40:1 ratio was optimal for restoring ovulation and normalizing FSH, LH, SHBG, free testosterone, and insulin levels. Ratios significantly skewed toward more DCI performed worse on most outcomes.
A 2024 prospective study of 34 women with PCOS Phenotype A given a 40:1 MYO/DCI combination for 3 months found significant improvements in LH, testosterone, free androgen index, and HOMA-IR.
Practical implication: When selecting an inositol product, look for a combination that provides MYO and DCI in a 40:1 ratio. The typical dosage used in studies is 2g of MYO plus 50mg of DCI twice daily (total 4g MYO and 100mg DCI per day). Products providing DCI at higher proportions than this are not supported by current evidence and may be counterproductive.
How Does Inositol for PCOS Compare to Metformin?
This is a question I am frequently asked. The 2024 systematic review for the International PCOS Guidelines found that metformin may have some advantages over inositol for waist-hip ratio and hirsutism, but likely no meaningful difference in reproductive outcomes (ovulation, pregnancy rates). Importantly, myo-inositol caused significantly fewer gastrointestinal side effects than metformin.
For women seeking to improve insulin sensitivity and ovulatory function with a well-tolerated, over-the-counter option, myo-inositol in the 40:1 combination is a reasonable first-line approach to pursue alongside dietary and lifestyle changes.
Who Benefits Most from Inositol Supplementation?
Based on the current evidence, women with PCOS who are most likely to benefit from inositol are those with insulin resistance (elevated fasting insulin, high HOMA-IR), irregular ovulation or anovulation, and those trying to conceive. Women with the lean PCOS phenotype may also benefit, as insulin resistance is present in approximately 80% of lean PCOS cases even when standard blood sugar panels appear normal.
Women with PCOS Phenotype D (non-hyperandrogenic, primarily ovulatory dysfunction) may benefit primarily from MYO for FSH support, while women with pronounced androgen excess may benefit more from the 40:1 combination.
The Bottom Line on Myo and D-Chiro Inositol
What to take: Myo-inositol and D-chiro-inositol in a 40:1 ratio, typically providing 4g MYO and 100mg DCI per day in divided doses.
What to avoid: High-dose DCI alone. The evidence does not support this approach, and emerging research suggests it may harm oocyte quality.
Realistic expectations: Improvements in insulin sensitivity and menstrual regularity are typically seen within 3 – 6 months. Inositol is not a rapid-onset treatment.
Important caveat: The overall evidence base remains limited. Inositol supplementation should be part of a comprehensive approach that includes dietary changes and, ideally, be personalized based on your specific PCOS phenotype and lab results.
References for Myo and D-Chiro Inositol:
- Fitz V et al. (2024). Inositol for PCOS: Systematic Review for 2023 International Evidence-Based PCOS Guidelines. J Clin Endocrinol Metab 109(6):1630-1655. PMID: 38163998
- Lete I et al. (2024). Update on the combination of myo-inositol/D-chiro-inositol for PCOS. Gynecol Endocrinol 40(1):2301554. PMID: 38239032 | Nordio M et al. (2019). The 40:1 myo-inositol/D-chiro-inositol plasma ratio restores ovulation in PCOS. Eur Rev Med Pharmacol Sci. PMID: 31298405
- Pustotina O et al. (2024). Effects of MYO/DCI 40:1 on hormonal and metabolic profile in PCOS Phenotype A. Gynecol Obstet Invest 89(2):131-139.
